eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID

Posted: February 22, 2023 at 12:15 am

Results presented at 30th Conference on Retroviruses and Opportunistic Infections (CROI) Results presented at 30th Conference on Retroviruses and Opportunistic Infections (CROI)

Go here to see the original:
eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID

Related Posts